Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Verona Pharma ( (VRNA) ) has issued an announcement.
On September 5, 2025, Verona Pharma‘s Board of Directors approved an amendment to the Employee Change in Control Severance Benefit Plan, extending the severance benefits period from twelve to twenty-four months and increasing the minimum severance period from three to six months. This amendment is contingent upon the closing of a transaction agreement with Merck Sharp & Dohme LLC and Vol Holdings LLC, and will be void if the agreement is terminated before closing.
The most recent analyst rating on (VRNA) stock is a Hold with a $107.00 price target. To see the full list of analyst forecasts on Verona Pharma stock, see the VRNA Stock Forecast page.
Spark’s Take on VRNA Stock
According to Spark, TipRanks’ AI Analyst, VRNA is a Neutral.
Verona Pharma’s stock is bolstered by strong revenue growth and a successful product launch, contributing to positive momentum. However, profitability challenges, high valuations, and potential overbought conditions temper enthusiasm. The company’s improved financial flexibility is a key strength, though ongoing operating losses and high SG&A expenses are notable risks.
To see Spark’s full report on VRNA stock, click here.
More about Verona Pharma
Verona Pharma plc operates in the pharmaceutical industry, focusing on the development of respiratory treatments.
Average Trading Volume: 3,503,394
Technical Sentiment Signal: Buy
Current Market Cap: $9.14B
See more data about VRNA stock on TipRanks’ Stock Analysis page.